NC–(n = 31) | NC+(n = 13) | MCI–(n = 13) | MCI+(n = 23) | AD dementia(n = 32) | OD(n = 13) | |
---|---|---|---|---|---|---|
Female, n (%) | 19 (61%) | 9 (69%) | 7 (54%) | 13 (56%) | 21 (66%) | 5 (39%) |
Age (years) | 69.1 ± 6.3 | 74.6 ± 6.9 | 70.1 ± 5.0 | 70.6 ± 6.2 | 72.8 ± 7.1 | 65.4 ± 4.5 |
Caucasian, n (%) | 28 (90%) | 13 (100%) | 12 (92%) | 23 (100%) | 30 (94%) | 13 (100%) |
Has at least one APOE ε4 allele, % | 26% | 38% | 3/10 (30%) | 52% | 72% | 31% |
Education (years) | 15.7 ± 3.3 | 15.4 ± 3.2 | 15.5 ± 3.2 | 15.0 ± 2.8 | 14.7 ± 3.8 | 15.4 ± 1.7 |
MMSE | 28.9 ± 1.8 | 28.5 ± 1.8 | 27.4 ± 2.1 | 26.4 ± 2.5 | 21.7 ± 4.9 | 23.2 ± 6.3 |
Recruiting center, n | ||||||
Emory | 9 | 3 | 7 | 7 | 10 | 8 |
Penn | 12 | 0 | 6 | 6 | 12 | 5 |
WU | 10 | 10 | 0 | 10 | 10 | 0 |
Emory AD biomarkers (Luminex) | ||||||
Aβ42 (pg/mL) | 301.3 ± 106.6 | 189.1 ± 134.8 | 306.3 ± 98.5 | 184.1 ± 68.6 | 171.3 ± 37.6 | 232.2 ± 114.9 |
t-Tau (pg/mL) | 48.5 ± 22.4 | 77.3 ± 53.3 | 63.8 ± 27.9 | 150.4 ± 81.6 | 148.8 ± 52.3 | 90.8 ± 106.0 |
p-Tau181 (pg/mL) | 28.0 ± 10.1 | 53.4 ± 26.9 | 32.5 ± 6.9 | 63.3 ± 19.3 | 74.7 ± 16.6 | 27.6 ± 15.7 |
Penn AD biomarkers (Luminex) | ||||||
Aβ42 (pg/mL) | 262.6 ± 72.5 | N/A | 242.1 ± 53.1 | 119.6 ± 18.0 | 121.9 ± 35.0 | 310.6 ± 72.9 |
t-Tau (pg/mL) | 54.4 ± 13.1 | N/A | 76.9 ± 34.8 | 96.6 ± 64.9 | 117.9 ± 41.4 | 66.2 ± 28.3 |
p-Tau181 (pg/mL) | 19.3 ± 14.4 | N/A | 33.9 ± 34.2 | 36.6 ± 21.1 | 45.6 ± 22.6 | 15.2 ± 4.5 |
WU AD biomarkers (ELISA) | ||||||
Aβ42 (pg/mL) | 736.9 ± 152.7 | 369.2 ± 87.5 | N/A | 349.0 ± 121.8 | 291.7 ± 74.4 | N/A |
t-Tau (pg/mL) | 282.8 ± 115.7 | 359.5 ± 230.3 | N/A | 615.2 ± 177.7 | 628.2 ± 363.1 | N/A |
p-Tau181 (pg/mL) | 54.4 ± 19.1 | 74.7 ± 40.7 | N/A | 107.4 ± 52.3 | 90.7 ± 52.7 | N/A |